- Anindya Chatterjee Brings Over Thirteen Years of Capital Markets
Experience to AOBO - - New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction
NEW YORK, June 9 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOB" or "the Company"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced the appointment of Anindya Chatterjee to Chief Strategy Officer, effective May 23, 2008. Based in New York, Anindya Chatterjee will report to Lily Li, Chief Financial Officer, Chief Operating Officer and co-founder of the Company.
Anindya Chatterjee will work closely with AOBO's management team to shape and execute the Company's core growth initiatives, including acquisition-led expansion and capital markets strategy. Further, he will also serve as the Company's interface with the investment community, playing a crucial role in enhancing investor communications and transparency.
Anindya Chatterjee brings more than thirteen years of capital markets experience to AOBO. He was previously a Managing Director in equity research at Jefferies & Co, where he headed Emerging Asian (China & India) equity research. He was also a Strategist and Economist focused on Non-Japan Asia for Bear Stearns & Company in Hong Kong. He held similar positions at IDEA INC. in New York, and NatWest Markets in Singapore, where he was the Emerging Markets Strategist and Regional Economist and Equity Strategist, respectively. He also was the Head of Research at ANZ Investment Bank in India, and held research positions at HSBC Securities and Smith New Court Securities.
Tony Liu, AOBO's Chief Executive Officer and Chairman stated, "We are excited to add Anindya to our core management team at this crucial time of rapid business expansion. Anindya brings a deep understanding our Company, our sector and our corporate culture in addition to his invaluable capital markets experience, and long-standing credibility among global institutional investors."
Anindya Chatterjee stated, "As an equity analyst, I have interacted regularly with AOBO's investors and management team, and I am very pleased to accept this strategic role at a Company with such strong fundamental performance, exciting growth prospects, and cohesive team. With my investment research experience and knowledge of the capital markets, I look forward to enhancing and executing AOBO's key growth initiatives, including the acquisition strategy and navigating the U.S. capital markets."
About American Oriental Bioengineering Inc.
American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com.
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2007, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
|SOURCE American Oriental Bioengineering, Inc.|
Copyright©2008 PR Newswire.
All rights reserved